- Home
- EPR vs RNA Comparison
EPR vs RNA Comparison
Compare EPR & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPR
- RNA
- Stock Information
- Founded
- EPR 1997
- RNA 2012
- Country
- EPR United States
- RNA United States
- Employees
- EPR N/A
- RNA N/A
- Industry
- EPR Real Estate Investment Trusts
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- EPR Real Estate
- RNA Health Care
- Exchange
- EPR Nasdaq
- RNA Nasdaq
- Market Cap
- EPR 4.4B
- RNA 4.0B
- IPO Year
- EPR 1997
- RNA 2020
- Fundamental
- Price
- EPR $55.11
- RNA $46.45
- Analyst Decision
- EPR Buy
- RNA Strong Buy
- Analyst Count
- EPR 11
- RNA 17
- Target Price
- EPR $56.94
- RNA $69.53
- AVG Volume (30 Days)
- EPR 955.8K
- RNA 3.6M
- Earning Date
- EPR 10-29-2025
- RNA 11-06-2025
- Dividend Yield
- EPR 6.43%
- RNA N/A
- EPS Growth
- EPR N/A
- RNA N/A
- EPS
- EPR 2.03
- RNA N/A
- Revenue
- EPR $701,405,000.00
- RNA $10,729,000.00
- Revenue This Year
- EPR $5.07
- RNA N/A
- Revenue Next Year
- EPR $2.56
- RNA $108.74
- P/E Ratio
- EPR $27.08
- RNA N/A
- Revenue Growth
- EPR 1.35
- RNA 1.23
- 52 Week Low
- EPR $41.75
- RNA $21.51
- 52 Week High
- EPR $61.24
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- EPR 43.24
- RNA 57.39
- Support Level
- EPR $54.88
- RNA $38.94
- Resistance Level
- EPR $58.57
- RNA $47.96
- Average True Range (ATR)
- EPR 0.99
- RNA 2.24
- MACD
- EPR -0.18
- RNA 0.44
- Stochastic Oscillator
- EPR 3.53
- RNA 83.15
About EPR EPR Properties
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.